<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Sterile" exact="alpha" post="motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is"/>
 <result pre="by phosphorylation. Combinations of a CDK4/6 inhibitor with nucleoside or" exact="folate" post="antimetabolites potently enhanced drug efficacy, resulting in highly synergic"/>
 <result pre="treatments. SAMHD1 antimetabolite CDK4/6 pemetrexed HIV cancer 1. Introduction Sterile" exact="alpha" post="motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) is"/>
 <result pre="inactivation of a number of different nucleoside analogues [30,31], including" exact="cytarabine" post="(Cytosar-U®,Ara-C), a first line therapeutic agent for acute myelogenous"/>
 <result pre="impaired the efficacy of anti-folate inhibitors such as pemetrexed and" exact="methotrexate" post="(Figure 2B). Calculation of 50% effective concentrations (EC50) of"/>
 <result pre="affected the efficacy of anti-folate drugs such as pemetrexed and" exact="methotrexate" post="(Table 1). 2.2. SAMHD1 Is Required for Antiviral Activity"/>
 <result pre="[14]. The antiviral activity of the highly selective CDK4/6 inhibitor" exact="palbociclib" post="is dependent on SAMHD1 expression [14,19] (Figure 3A). Thus,"/>
 <result pre="3A). Thus, the efficacy of two other specific CDK4/6 inhibitors," exact="ribociclib" post="and abemaciclib, was also evaluated in the presence or"/>
 <result pre="SAMHD1. The three agents were tested at the concentration where" exact="palbociclib" post="showed the highest efficacy in cell culture (1 μM,"/>
 <result pre="3B). Interestingly, similar results were obtained when the multi-kinase inhibitor" exact="midostaurin" post="was evaluated (Figure S1A), suggesting that activity of multiple"/>
 <result pre="SAMHD1 expression and phosphorylation was measured by Western blot. Both" exact="palbociclib" post="and midostaurin blocked SAMHD1 phosphorylation, whereas SAMHD1 protein expression"/>
 <result pre="and phosphorylation was measured by Western blot. Both palbociclib and" exact="midostaurin" post="blocked SAMHD1 phosphorylation, whereas SAMHD1 protein expression was not"/>
 <result pre="decreased expression of Rb, a substrate of CDK6, suggesting that" exact="palbociclib" post="and midostaurin also affect CDK6-mediated CDK2 phosphorylation of SAMHD1"/>
 <result pre="of Rb, a substrate of CDK6, suggesting that palbociclib and" exact="midostaurin" post="also affect CDK6-mediated CDK2 phosphorylation of SAMHD1 (Figure 3C,"/>
 <result pre="inhibition of its phosphorylation. Thus, we evaluated the capacity of" exact="palbociclib" post="to modify the activity of antimetabolites. Antiviral activity of"/>
 <result pre="modify the activity of antimetabolites. Antiviral activity of pemetrexed and" exact="fluorouracil" post="were evaluated alone or in combination with palbociclib in"/>
 <result pre="pemetrexed and fluorouracil were evaluated alone or in combination with" exact="palbociclib" post="in primary macrophages. Pemetrexed inhibited HIV-1 replication in a"/>
 <result pre="4A, black line). Combination of pemetrexed with increasing concentrations of" exact="palbociclib" post="(EC50 = 0.12 µM) enhanced the antiviral potency of"/>
 <result pre="combination index (CI) indicated strong synergy (CI ≤ 0.041 for" exact="palbociclib" post="at 0.04 µM combined with different concentrations of pemetrexed,"/>
 <result pre="with different concentrations of pemetrexed, Table 2). Interestingly, pemetrexed and" exact="palbociclib" post="activity, as well as the synergistic effect observed in"/>
 <result pre="panels). Furthermore, the combination of pemetrexed with the multi-kinase inhibitor" exact="midostaurin" post="(EC50 = 0.62 µM) also showed a highly synergistic"/>
 <result pre="panels). On the other hand, combination of the nucleoside analogue" exact="fluorouracil" post="or the multikinase inhibitor midostaurin with palbociclib showed more"/>
 <result pre="combination of the nucleoside analogue fluorouracil or the multikinase inhibitor" exact="midostaurin" post="with palbociclib showed more limited effects, i.e., palbociclib partially"/>
 <result pre="the nucleoside analogue fluorouracil or the multikinase inhibitor midostaurin with" exact="palbociclib" post="showed more limited effects, i.e., palbociclib partially enhanced the"/>
 <result pre="multikinase inhibitor midostaurin with palbociclib showed more limited effects, i.e.," exact="palbociclib" post="partially enhanced the antiviral potency of fluorouracil or midostaurin"/>
 <result pre="limited effects, i.e., palbociclib partially enhanced the antiviral potency of" exact="fluorouracil" post="or midostaurin in the presence of SAMHD1 (Figure S2)."/>
 <result pre="i.e., palbociclib partially enhanced the antiviral potency of fluorouracil or" exact="midostaurin" post="in the presence of SAMHD1 (Figure S2). Combination index"/>
 <result pre="thus we evaluated cytotoxic efficacy of the antimetabolites pemetrexed and" exact="fluorouracil" post="in combination with the CDK4/6 inhibitor palbociblib in the"/>
 <result pre="differences between them (Table S1). The combination of pemetrexed with" exact="palbociclib" post="enhanced the cytotoxicity of the antimetabolite in all cell"/>
 <result pre="when antiviral efficacy was measured (Table 3). The combination of" exact="fluorouracil" post="with palbociclib enhanced fluorouracil potency in TZM-bl and T47D"/>
 <result pre="efficacy was measured (Table 3). The combination of fluorouracil with" exact="palbociclib" post="enhanced fluorouracil potency in TZM-bl and T47D cells but"/>
 <result pre="measured (Table 3). The combination of fluorouracil with palbociclib enhanced" exact="fluorouracil" post="potency in TZM-bl and T47D cells but not in"/>
 <result pre="inhibitor palbociclib, protein expression in primary macrophages treated with pemetrexed," exact="fluorouracil" post="and palbociclib, alone or in combination was evaluated (Figure"/>
 <result pre="alone or in combination was evaluated (Figure 6A). As expected," exact="palbociclib" post="alone inhibited phosphorylation of pRb and SAMHD1, therefore activating"/>
 <result pre="and subsequently reducing the intracellular dNTP pool. Interestingly, pemetrexed and" exact="fluorouracil" post="treatment resulted in different effects, i.e., while fluorouracil acts"/>
 <result pre="pemetrexed and fluorouracil treatment resulted in different effects, i.e., while" exact="fluorouracil" post="acts similarly to palbociclib, pemetrexed did not decrease the"/>
 <result pre="other hand, when two compounds directly affecting SAMHD1 phosphorylation (i.e.," exact="fluorouracil" post="and palbociclib) are combined, the synergic effect is less"/>
 <result pre="also anti-folate drugs. Interestingly, antifolate drugs such as pemetrexed or" exact="methotrexate" post="showed increased potency in SAMHD1-expressing cells, whereas nucleoside analogues"/>
 <result pre="(AraC and clofarabine) and other types of hematological cancers like" exact="nelarabine" post="for T-lymphoblastic lymphoma, cladribine used in the treatment of"/>
 <result pre="other types of hematological cancers like nelarabine for T-lymphoblastic lymphoma," exact="cladribine" post="used in the treatment of hairy cell leukemia and"/>
 <result pre="serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA), penicillin and" exact="streptomycin" post="(Thermo Fisher Scientific, Waltham, MA, USA) and differentiated to"/>
 <result pre="technique as described elsewhere (22). 4.2. Drugs 33-Azido-3-deoxythymidine (zidovudine, AZT)," exact="nevirapine" post="(NVP), 1-beta-D-Arabinofuranosylcytosine (AraC), 9-beta-D-Arabinofuranosyl-2-fluoroadenine (fludarabine), 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine (nelarabine), 2-Chloro-2′-deoxyadenosine (cladribine),"/>
 <result pre="described elsewhere (22). 4.2. Drugs 33-Azido-3-deoxythymidine (zidovudine, AZT), nevirapine (NVP)," exact="1-beta-D-Arabinofuranosylcytosine" post="(AraC), 9-beta-D-Arabinofuranosyl-2-fluoroadenine (fludarabine), 2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine (nelarabine), 2-Chloro-2′-deoxyadenosine (cladribine), 2-chloro-9-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (clofarabine),"/>
 <result pre="Drugs 33-Azido-3-deoxythymidine (zidovudine, AZT), nevirapine (NVP), 1-beta-D-Arabinofuranosylcytosine (AraC), 9-beta-D-Arabinofuranosyl-2-fluoroadenine (fludarabine)," exact="2-Amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine" post="(nelarabine), 2-Chloro-2′-deoxyadenosine (cladribine), 2-chloro-9-(2-Deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (clofarabine), 2′,2′-Difluorodeoxycytidine (gemcitabine), 5-Fluoro-2-desoxyuridine (floxuridine),"/>
 <result pre="and 4′-N-benzoylstaurosporine (midostaurin) were purchased from Sigma-Aldrich (Madrid, Spain). Palbociclib," exact="ribociclib" post="and abemaciclib were purchased from Selleckchem (Munich, Germany). 4-amino-10-methylfolic"/>
 <result pre="(midostaurin) were purchased from Sigma-Aldrich (Madrid, Spain). Palbociclib, ribociclib and" exact="abemaciclib" post="were purchased from Selleckchem (Munich, Germany). 4-amino-10-methylfolic acid (methotrexate)"/>
 <result pre="Palbociclib, ribociclib and abemaciclib were purchased from Selleckchem (Munich, Germany)." exact="4-amino-10-methylfolic acid" post="(methotrexate) was purchased from Eurodiagnosticos SL (Madrid, Spain). 4.3."/>
 <result pre="online at https://www.mdpi.com/2072-6694/12/3/713/s1, Figure S1: Efficacy of the multi-kinase inhibitor" exact="midostaurin" post="depends on SAMHD1 expression, Figure S2: Relative effect of"/>
 <result pre="Cycle2017161029103810.1080/15384101.2017.131440728436707 28.HeroldN.RuddS.G.LjungbladL.SanjivK.MyrbergI.H.PaulinC.B.J.HeshmatiY.HagenkortA.KutznerJ.PageB.D.G.et al.Targeting SAMHD1 with the Vpx protein to improve" exact="cytarabine" post="therapy for hematological malignanciesNat. Med.20172325626310.1038/nm.426528067901 29.SchneiderC.OellerichT.BaldaufH.-M.SchwarzS.-M.ThomasD.FlickR.BohnenbergerH.KaderaliL.StegmannL.CremerA.et al.SAMHD1 is a"/>
 <result pre="for hematological malignanciesNat. Med.20172325626310.1038/nm.426528067901 29.SchneiderC.OellerichT.BaldaufH.-M.SchwarzS.-M.ThomasD.FlickR.BohnenbergerH.KaderaliL.StegmannL.CremerA.et al.SAMHD1 is a biomarker for" exact="cytarabine" post="response and a therapeutic target in acute myeloid leukemiaNat."/>
 <result pre="enzyme inhibitorsAdv. Enzym. Regul.198422275510.1016/0065-2571(84)90007-4 Figure 1 (A) Degradation of sterile" exact="alpha" post="motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) by"/>
 <result pre="As in (A), dose response of two other CDK4/6 inhibitors," exact="ribociclib" post="(left panel) and abemaciclib (right panel), in wild-type (■)"/>
 <result pre="response of two other CDK4/6 inhibitors, ribociclib (left panel) and" exact="abemaciclib" post="(right panel), in wild-type (■) or SAMHD1-depleted (Δ) MDMs."/>
 <result pre="of two independent donors performed in duplicate is shown. (C)" exact="Palbociclib" post="blocks SAMHD1 inactivation by phosphorylation. Western blot analysis of"/>
 <result pre="of untreated MDMs (no drug, ND) or macrophages treated with" exact="palbociclib" post="at the indicated doses. Membranes were blotted with an"/>
 <result pre="antiviral activity. Inhibition of HIV infection with increasing doses of" exact="palbociclib" post="and pemetrexed was measured. Percentage of GFP+ cells relative"/>
 <result pre="(white bars) or in combination with a fixed dose of" exact="palbociclib" post="0.04 µM (black bars), in the presence (left panel)"/>
 <result pre="antiviral activity. Inhibition of HIV infection with increasing doses of" exact="midostaurin" post="and pemetrexed was measured. Percentage of GFP+ cells relative"/>
 <result pre="(white bars) or in combination with a fixed dose of" exact="midostaurin" post="0.2 µM (black bars), in the presence (left panel)"/>
 <result pre="and MDA-MB-468 cell lines, respectively. Left panels, cytotoxic activity of" exact="palbociclib" post="alone (5 µM, white bars), pemetrexed alone (black bars"/>
 <result pre="the same concentration (grey bars). Right panels, cytotoxic activity of" exact="palbociclib" post="alone (5 µM, white bars), fluorouracil alone (5 µM,"/>
 <result pre="panels, cytotoxic activity of palbociclib alone (5 µM, white bars)," exact="fluorouracil" post="alone (5 µM, black bars) or the combination of"/>
 <result pre="for drug synergy. (A) Protein expression in MDMs treated with" exact="palbociclib" post="(PD) at 1 µM, pemetrexed (PTX) and fluorouracil (FU),"/>
 <result pre="treated with palbociclib (PD) at 1 µM, pemetrexed (PTX) and" exact="fluorouracil" post="(FU), both at 5µM and the corresponding drug combinations"/>
 <result pre="and thus synergy with anticancer drugs affecting SAMHD1 phosphorylation as" exact="palbociclib" post="is higher compared to compounds also targeting SAMHD1 function"/>
 <result pre="0.95 1 1 AraC Pyrimidine (dC) 3.24 0.11 - 30" exact="Nelarabine" post="Purine (dG) 13.96 1.83 - 8 Cladribine Purine (dA)"/>
 <result pre="0.11 - 30 Nelarabine Purine (dG) 13.96 1.83 - 8" exact="Cladribine" post="Purine (dA) 0.029 0.007 - 4 Clofarabine Purine (dG)"/>
 <result pre="0.006 - 6 Floxuridine Pyrimidine (dU) 0.73 20.28 28 -" exact="Fluorouracil" post="Pyrimidine (dU) 2.40 &amp;gt;25 &amp;gt;10 - Pemetrexed Anti-folate 0.25"/>
 <result pre="2.40 &amp;gt;25 &amp;gt;10 - Pemetrexed Anti-folate 0.25 &amp;gt;25 &amp;gt;100 -" exact="Methotrexate" post="Anti-folate 0.42 79.24 190 - EC50; Effective concentration required"/>
 <result pre="(+/-). cancers-12-00713-t002_Table 2Table 2 Combination index values for pemetrexed and" exact="fluorouracil" post="combinations with palbociclib and midostaurin. Macrophages were treated with"/>
 <result pre="2 Combination index values for pemetrexed and fluorouracil combinations with" exact="palbociclib" post="and midostaurin. Macrophages were treated with the different at"/>
 <result pre="different at indicated concentrations in combination with 0.04 µM of" exact="palbociclib" post="or 0.2 µM of midostaurin and infected with HIV-1"/>
 <result pre="combination with 0.04 µM of palbociclib or 0.2 µM of" exact="midostaurin" post="and infected with HIV-1 for 48 h. Drug efficacy was"/>
 <result pre="(CI) Effect Pemetrexed 25 0.0049 Synergy + 5 0.0097 Synergy" exact="Palbociclib" post="0.04 µM 1 0.0285 Synergy 0.2 0.0415 Synergy 0.04"/>
 <result pre="0.0673 Synergy Pemetrexed 25 0.079 Synergy + 5 0.069 Synergy" exact="Midostaurin" post="0.2 µM 1 0.056 Synergy 0.2 0.045 Synergy 0.04"/>
 <result pre="µM 1 0.056 Synergy 0.2 0.045 Synergy 0.04 0.064 Synergy" exact="Fluorouracil" post="5 1.871 Antagonism + 1 0.572 Synergy Palbociclib 0.04"/>
 <result pre="0.064 Synergy Fluorouracil 5 1.871 Antagonism + 1 0.572 Synergy" exact="Palbociclib" post="0.04 µM 0.2 0.658 Synergy 0.04 1.818 Antagonism 0.008"/>
 <result pre="µM 0.2 0.658 Synergy 0.04 1.818 Antagonism 0.008 2.967 Antagonism" exact="Midostaurin" post="5 2.074 Antagonism + 1 0.427 Synergy Palbociclib 0.04"/>
 <result pre="2.967 Antagonism Midostaurin 5 2.074 Antagonism + 1 0.427 Synergy" exact="Palbociclib" post="0.04 µM 0.2 0.223 Synergy 0.04 0.419 Synergy 0.008"/>
 <result pre="additive. cancers-12-00713-t003_Table 3Table 3 Combination index values for pemetrexed and" exact="fluorouracil" post="combinations with palbociclib. TZM-bl, MDA-MB-468 and T47D cells were"/>
 <result pre="T47D cells were treated with indicated concentrations of pemetrexed or" exact="fluorouracil" post="in combination with 5 µM of palbociclib. Cytotoxic effect"/>
 <result pre="Effect TZM-bl Pemetrexed 1 0.806 Synergy + 0.2 0.689 Synergy" exact="Palbociclib" post="5 µM 0.04 0.71 Synergy 0.008 0.72 Synergy Fluorouracil"/>
 <result pre="Synergy Palbociclib 5 µM 0.04 0.71 Synergy 0.008 0.72 Synergy" exact="Fluorouracil" post="5 0.726 Synergy + 1 0.766 Synergy Palbociclib 5"/>
 <result pre="0.72 Synergy Fluorouracil 5 0.726 Synergy + 1 0.766 Synergy" exact="Palbociclib" post="5 µM 0.2 0.764 Synergy 0.04 0.735 Synergy T47D"/>
 <result pre="Synergy T47D Pemetrexed 5 0.783 Synergy + 1 0.707 Synergy" exact="Palbociclib" post="5 µM 0.2 0.779 Synergy 0.04 0.874 Synergy Fluorouracil"/>
 <result pre="Synergy Palbociclib 5 µM 0.2 0.779 Synergy 0.04 0.874 Synergy" exact="Fluorouracil" post="25 0.848 Synergy + 5 0.804 Synergy Palbociclib 5"/>
 <result pre="0.874 Synergy Fluorouracil 25 0.848 Synergy + 5 0.804 Synergy" exact="Palbociclib" post="5 µM 1 0.966 Additive 0.2 1.01 Additive MDA-MB-468"/>
 <result pre="Additive MDA-MB-468 Pemetrexed 1 0.886 Synergy + 0.2 0.886 Synergy" exact="Palbociclib" post="5 µM 0.04 0.921 Synergy 0.008 1.01 Additive Fluorouracil"/>
 <result pre="Synergy Palbociclib 5 µM 0.04 0.921 Synergy 0.008 1.01 Additive" exact="Fluorouracil" post="25 2.844 Antagonism + 5 1.745 Antagonism Palbociclib 5"/>
 <result pre="1.01 Additive Fluorouracil 25 2.844 Antagonism + 5 1.745 Antagonism" exact="Palbociclib" post="5 µM 1 1.356 Antagonism 0.2 1.125 Antagonism CI"/>
</results>
